BIOA B — BioArctic AB Share Price
0.000.00%
Last trade - 00:00- SEK16.72bn
- SEK16.26bn
- SEK257.35m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.52 | ||
| PEG Ratio (f) | 0.27 | ||
| EPS Growth (f) | 338.67% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 18.69 | ||
| Price to Tang. Book | 18.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 64.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.41% | ||
| Return on Equity | -18.24% | ||
| Operating Margin | -88.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 62.35 | 23.15 | 228.29 | 616 | 257.35 | 1,978.97 | 1,399.3 | -1.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -48.9 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Directors
- Wenche Rolfsen CHM (69)
- Gunilla Osswald CEO (59)
- Ivar Verner NVC (73)
- Jan Mattsson CFO (56)
- Lars Lannfelt SVP (71)
- Christer Moller CSO (61)
- Oskar Bosson VPR
- Mikael Moge VPR (53)
- Johanna Falting VRD (48)
- Gunilla Andersson DHR (59)
- Christine Lind DIR
- Tomas Odergren OTH
- Par Gellerfors DRC (73)
- Hakan Englund IND
- Mikael Smedeby IND (52)
- Eugen Steiner IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 22nd, 2000
- Public Since
- October 12th, 2017
- No. of Shareholders
- 23,833
- No. of Employees
- 107
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 88,389,035
- Address
- Warfvinges vag 35, STOCKHOLM, 112 51
- Web
- https://www.bioarctic.se/
- Phone
- +46 86956930
- Contact
- Oskar Bosson
- Auditors
- Grant Thornton Sweden AB
Upcoming Events for BIOA B
BioArctic AB Annual Shareholders Meeting
BioArctic AB Annual Shareholders Meeting
BioArctic AB Capital Markets Day 2025
Q2 2025 BioArctic AB Earnings Release
Similar to BIOA B
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
What is the BioArctic AB share price?
As of Today at 01:35 UTC, shares in BioArctic AB are trading at SEK189.20. This share price information is delayed by 15 minutes.
How has the BioArctic AB share price performed this year?
Shares in BioArctic AB last closed at SEK189.20 and the price had moved by -2.32% over the past 365 days. In terms of relative price strength the BioArctic AB share price has underperformed the FTSE Global All Cap Index by -4.77% over the past year.
What are the analyst and broker recommendations for BioArctic AB?
The overall consensus recommendation for BioArctic AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioArctic AB dividend yield?
BioArctic AB does not currently pay a dividend.
Does BioArctic AB pay a dividend?
BioArctic AB does not currently pay a dividend.
When does BioArctic AB next pay dividends?
BioArctic AB does not currently pay a dividend.
How do I buy BioArctic AB shares?
To buy shares in BioArctic AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioArctic AB?
As of the previous close price of SEK189.20, shares in BioArctic AB had a market capitalisation of SEK16.72bn.
Where are BioArctic AB shares listed?
Here are the trading details for BioArctic AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BIOA B
What kind of share is BioArctic AB?
Based on an overall assessment of its quality, value and momentum BioArctic AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioArctic AB share price forecast for 2025?
The analyst consensus target price for shares in BioArctic AB is SEK302.43. That is 59.85% above the last closing price of SEK189.20.
Analysts covering BioArctic AB currently have a consensus Earnings Per Share (EPS) forecast of SEK10.92 for the next financial year.
Find out moreWhat is the trend in the BioArctic AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioArctic AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +19.74%.
As of the last closing price of SEK189.20, shares in BioArctic AB were trading +1.74% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioArctic AB PE Ratio?
The BioArctic AB PE ratio based on its reported earnings over the past 12 months is 20.52. The shares last closed at SEK189.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioArctic AB?
BioArctic AB's management team is headed by:
- Wenche Rolfsen - CHM
- Gunilla Osswald - CEO
- Ivar Verner - NVC
- Jan Mattsson - CFO
- Lars Lannfelt - SVP
- Christer Moller - CSO
- Oskar Bosson - VPR
- Mikael Moge - VPR
- Johanna Falting - VRD
- Gunilla Andersson - DHR
- Christine Lind - DIR
- Tomas Odergren - OTH
- Par Gellerfors - DRC
- Hakan Englund - IND
- Mikael Smedeby - IND
- Eugen Steiner - IND